Some GLP-1 receptor agonists may hold promise as treatments for alcohol use disorder (AUD), a Swedish observational study ...

A new class of drugs is set to join their ranks and has the potential to eclipse them all—GLP-1 receptor agonists. These drugs mimic the action of a naturally occurring hormone, glucagon-like ...

The use of GLP-1-agonists was associated with a significantly reduced risk of hospitalisation due to alcohol use disorder. Semaglutide was associated with a 36% lower risk, and liraglutide with a ...

These are just some of the ways in which analysts forecast that the new wave of incredibly effective weight-loss drugs, known as GLP-1 agonists, might transform societies and save countries ...

Garrett H. Garner, MD, Medical Director at SimpleFixRx to review it all for accuracy. Dr, Garner said, "Glucagon-like peptide ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Continuing GLP-1 receptor agonist medications when undergoing an endoscopic procedure appeared safe in a meta-analysis.

The global GLP-1 receptor agonist market is poised for extraordinary expansion, driven by an increase in therapeutic applications and favorable market projections. Recent analysis indicates a ...

Semaglutide and liraglutide are associated with reduced AUD and SUD-related hospitalization risks, unlike other GLP-1 agonists and AUD medications. The study followed 227,886 individuals with AUD ...

Novo Nordisk (NVO) teased some new details about a potential Ozempic successor during a call with investors Tuesday.

The category is expected to scale to $8.7 billion by 2027. The market for GLP-1 agonist drugs also continues to grow and is expected to exceed $100 billion by 2030. NBJ's report aims to educate ...